Strategic positioning for clinical trials in 2021

MyMD will commence a Phase 2 clinical trial of MYMD-1 in COVID19 associated depression in 2021. In addition, we expect to advance MYMD-1 into a phase 2 clinical trial for treatment of diabetes, rheumatoid arthritis, Sarcopenia (aging) and multiple sclerosis. We will also execute studies of Supera-CBD that will enable submission of an Investigational New Drug Application (IND) to the FDA for a Phase 1 clinical trial in epilepsy, addiction, autism and anxiety disorders.

We’re making news in the biotech pharmaceuticals industry

MyMD Pharmaceuticals Set to Join Russell Microcap® Index

The company will join the Russell Microcap® Index on June 28, 2021.

BioSpace: MyMD Pharma Develops Low-Toxicity, Plant-Based TNF-α Regulator

MYMD-1 addresses the root causes of autoimmune diseases by targeting pro-inflammatory cytokines.

Targeting TNF-Alpha Receptors & Multiple Sclerosis (MS)

Dr. Adam Kaplin, Chief Scientific Officer, shares his perspective on TNF-alpha and MS.

All News

  • This field is for validation purposes and should be left unchanged.